{"id":1016616,"date":"2026-11-03T07:01:01","date_gmt":"2026-11-03T12:01:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/"},"modified":"2026-11-03T07:01:01","modified_gmt":"2026-11-03T12:01:01","slug":"biontech-announces-third-quarter-2026-financial-results-and-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/","title":{"rendered":"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <b><br \/>\n            <i>Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer,<\/i><br \/>\n          <\/b><br \/>\n          <i> with pumitamig plus elfetabart drozuntecan<\/i>\n        <\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <b><br \/>\n            <i>Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead\u2019s TROP2-directed antibody-drug conjugate <\/i><br \/>\n          <\/b><br \/>\n          <i>sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval<\/i>\n        <\/li>\n<\/ul>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <b><br \/>\n            <i>Presented data demonstrating gotistobart nearly doubled median overall survival <\/i><br \/>\n          <\/b><br \/>\n          <i>versus chemotherapy in previously treated squamous non-small cell lung cancer<\/i>\n        <\/li>\n<\/ul>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <b><br \/>\n            <i>Launched variant-adapted COVID-19 vaccine for the 2026\/2027 vaccination season in multiple regions worldwide<\/i><br \/>\n          <\/b>\n        <\/li>\n<\/ul>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <b><br \/>\n            <i>Third quarter 2026 revenues of \u20ac1,289.2\u00a0million<sup>1<\/sup><\/i><br \/>\n          <\/b><br \/>\n          <i>, adjusted<sup>2<\/sup> R&amp;D expenses of \u20ac578.5\u00a0million (IFRS R&amp;D expenses of \u20ac748.1\u00a0million), and adjusted SG&amp;A<sup>3<\/sup> expenses of \u20ac178.5\u00a0million<\/i>\n        <\/li>\n<\/ul>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <b><br \/>\n            <i>Raised full-year 2026 revenue guidance midpoint and updated range to \u20ac1.7\u20131.9 billion, <\/i><br \/>\n          <\/b><br \/>\n          <i>and maintained strong financial position with cash, cash equivalents and security investments of \u20ac16.2\u00a0billion<sup>4<\/sup><\/i>\n        <\/li>\n<\/ul>\n<p align=\"center\">\n        <b>Conference call and webcast scheduled for November\u00a03, 2026, at 8:00 a.m. EST (2:00 p.m. CET)<\/b>\n      <\/p>\n<p align=\"justify\">\n        <b>MAINZ, Germany,\u00a0November\u00a03, 2026 (GLOBE NEWSWIRE)<\/b> &#8212;\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cGcAwz7quIiv0Ih9OY9gpjyrJCik9rwPqieuuK_9HGfB5tPacvTMqykHO-YfNJqrGOO_cVImE_InksZDU85s3qMzuD92OAzQ0h0194fjTRYcdBXfr7uFHmPpCv-5ykZ0\" rel=\"nofollow\" target=\"_blank\">BioNTech SE<\/a> (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today reported financial results for the three and nine months ended September 30, 2026 and provided an update on its corporate progress.<\/p>\n<p align=\"justify\">\u201cAs 2026 draws to a close, the achievement of numerous important milestones throughout the year demonstrates our commitment to advancing our oncology pipeline, and our combination therapy strategy continues to gain momentum, underscored by the announced first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate,\u201d said <b>Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech<\/b>. \u201cWith a growing pipeline, key registrational trials, strategic partnerships, and financial strength, BioNTech is well positioned for its next phase of growth as we advance toward becoming a diversified, multi-product company by 2030.\u201d<\/p>\n<p align=\"justify\">\n        <b>Financial Review for Third Quarter and Year-to-Date 2026<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td rowspan=\"2\" style=\"width:157px;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <i>in millions \u20ac, <\/i><br \/>\n            <br \/>\n            <i>except per share data<\/i>\n          <\/td>\n<td colspan=\"2\" style=\"width:222px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Third Quarter 2026<\/b>\n          <\/td>\n<td colspan=\"2\" style=\"width:222px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Third Quarter 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>IFRS Results<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Adjusted Results<\/b><br \/>\n            <sup><br \/>\n              <b>2<\/b><br \/>\n            <\/sup>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>IFRS Results<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Adjusted Results<\/b><br \/>\n            <sup><br \/>\n              <b>2<\/b><br \/>\n            <\/sup>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:157px;border-bottom: solid black 1pt\">\n            <b>Revenues<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,289.2<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,289.2<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,518.9<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,518.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:157px;border-bottom: solid black 1pt\">\n            <b>Net profit \/ (loss)<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">184.5<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">440.9<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(28.7)<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">752.5<\/td>\n<\/tr>\n<tr>\n<td style=\"width:157px;border-bottom: solid black 1pt\">\n            <b>Diluted profit \/ (loss) per share<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">0.73<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1.76<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(0.12)<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">3.11<\/td>\n<\/tr>\n<tr>\n<td style=\"width:157px;border-bottom: solid black 1pt\">\n            <b>Weighted average number of shares outstanding (in millions)<sup>5<\/sup><\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">251<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">251<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">241<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">242<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td rowspan=\"2\" style=\"width:157px;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <i>in millions \u20ac, <\/i><br \/>\n            <br \/>\n            <i>except per share data<\/i>\n          <\/td>\n<td colspan=\"2\" style=\"width:222px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Year-to-date 2026<\/b>\n          <\/td>\n<td colspan=\"2\" style=\"width:222px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Year-to-date 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>IFRS Results<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Adjusted Results<\/b><br \/>\n            <sup><br \/>\n              <b>2<\/b><br \/>\n            <\/sup>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>IFRS Results<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Adjusted Results<\/b><br \/>\n            <sup><br \/>\n              <b>2<\/b><br \/>\n            <\/sup>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:157px;border-bottom: solid black 1pt\">\n            <b>Revenues<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,512.9<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,512.9<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,962.5<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,962.5<\/td>\n<\/tr>\n<tr>\n<td style=\"width:157px;border-bottom: solid black 1pt\">\n            <b>Net loss<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,168.2)<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(615.9)<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(831.1)<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(27.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:157px;border-bottom: solid black 1pt\">\n            <b>Diluted loss per share<\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(4.63)<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(2.44)<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(3.45)<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(0.11)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:157px;border-bottom: solid black 1pt\">\n            <b>Weighted average number of shares outstanding (in millions)<sup>5<\/sup><\/b>\n          <\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">252<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">252<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">241<\/td>\n<td style=\"width:111px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">241<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">The figures below compare the third quarter of 2026 and the year-to-date period ended September\u00a030, 2026, to the corresponding prior year periods, except where noted.<\/p>\n<p align=\"justify\">\n        <b>Revenues<\/b> were \u20ac1,289.2 million for the third quarter of 2026, compared to \u20ac1,518.9 million. Year-to-date revenues were \u20ac1,512.9 million, compared to \u20ac1,962.5 million. The decreases were primarily driven by expected lower market demand for BioNTech\u2019s COVID-19 vaccines.<\/p>\n<p align=\"justify\">\n        <b>Research and development (\u201cR&amp;D\u201d) expenses<\/b> were \u20ac748.1 million for the third quarter of 2026, compared to \u20ac564.8 million. Year-to-date R&amp;D expenses were \u20ac1,856.1 million, compared to \u20ac1,599.5 million. R&amp;D expenses were mainly driven by higher expenses for the development of BioNTech\u2019s late-stage immuno-oncology (\u201cIO\u201d) and antibody-drug conjugate (\u201cADC\u201d) programs and impairment expenses related to intangible assets which are outside of BioNTech\u2019s strategic focus.<\/p>\n<p align=\"justify\">\n        <b>Adjusted R&amp;D expenses<\/b> were \u20ac578.5\u00a0million for the third quarter of 2026, compared to \u20ac479.4\u00a0million. Year-to-date adjusted R&amp;D expenses were \u20ac1,582.7\u00a0million, compared to \u20ac1,514.1\u00a0million. Adjusted R&amp;D expenses for both the third quarter and year-to-date period in 2026 exclude impairment expenses related to intangible assets which are outside of BioNTech\u2019s strategic focus.<\/p>\n<p align=\"justify\">\n        <b>Sales, general and administrative (\u201cSG&amp;A\u201d) expenses<\/b> were \u20ac178.5 million for the third quarter of 2026, compared to \u20ac148.5 million. Year-to-date SG&amp;A expenses were \u20ac527.1 million, compared to \u20ac406.5 million. The increases were mainly driven by the ongoing pre\u2011launch activities and commercial build-up, expenses associated with BioNTech\u2019s global initiative on scaling processes and ERP infrastructure to strengthen operational execution and the inclusion of operations from CureVac. This was partly offset by cost reductions resulting from the execution of initiatives related to BioNTech\u2019s pipeline prioritization.<\/p>\n<p align=\"justify\">\n        <b>Other operating result<\/b> was negative \u20ac134.3 million for the third quarter of 2026, compared to negative \u20ac704.2 million. Year-to-date other operating result was negative \u20ac358.6 million, compared to negative \u20ac730.1 million. The quarterly and year-to-date results were primarily driven by impairment losses and employee related restructuring costs derived from BioNTech\u2019s pipeline prioritization execution.<\/p>\n<p align=\"justify\">\n        <b>Adjusted other operating result<\/b> was negative \u20ac58.9 million for the third quarter of 2026, compared to negative \u20ac8.4 million. Year-to-date adjusted other operating result was negative \u20ac91.1 million, compared to negative \u20ac11.5 million. Adjusted other operating result for the third quarter of 2026 excludes impairment losses and employee-related costs related to BioNTech\u2019s pipeline prioritization execution as well as settlement expenses, while the comparable prior year result excludes employee-related costs and settlement expenses. Year-to-date periods in 2026 and 2025 exclude impairment losses, employee-related costs and settlement expenses, while 2025 also excludes a bargain purchase.<\/p>\n<p align=\"justify\">\n        <b>Net profit <\/b>was \u20ac184.5 million for the third quarter of 2026, compared to a net loss of \u20ac28.7 million. Year-to-date net loss was \u20ac1,168.2 million, compared to a net loss of \u20ac831.1 million.<\/p>\n<p align=\"justify\">\n        <b>Adjusted net profit<\/b> was \u20ac440.9 million for the third quarter of 2026, compared to an adjusted net profit of \u20ac752.5 million. Year-to-date adjusted net loss was \u20ac615.9 million, compared to an adjusted net loss of \u20ac27.1 million.<\/p>\n<p align=\"justify\">\n        <b>Diluted profit per share<\/b> was \u20ac0.73 for the third quarter of 2026, compared to a diluted loss per share of \u20ac0.12. Year-to-date diluted loss per share was \u20ac4.63, compared to a diluted loss per share of \u20ac3.45.<\/p>\n<p align=\"justify\">\n        <b>Adjusted diluted profit per share<\/b> was \u20ac1.76 for the third quarter of 2026, compared to adjusted diluted profit per share of \u20ac3.11. Year-to-date adjusted diluted loss per share was \u20ac2.44, compared to an adjusted diluted loss per share of \u20ac0.11.<\/p>\n<p align=\"justify\">\n        <b>Cash, cash equivalents and security investments <\/b>as of September\u00a030, 2026 were \u20ac16,163.8\u00a0million, comprising \u20ac10,200.8\u00a0million in cash and cash equivalents, \u20ac4,390.2\u00a0million in current security investments disclosed as financial assets and \u20ac1,572.8\u00a0million\u00a0in non-current security investments disclosed as financial assets.<\/p>\n<p align=\"justify\">\n        <b>Shares outstanding<\/b> as of September\u00a030, 2026 were 247,928,180, excluding 11,099,307 shares held in treasury. <\/p>\n<p align=\"justify\">\n        <b>In May 2026, BioNTech entered into a share repurchase program<\/b>, pursuant to which the Company may purchase American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share of the Company, in the amount of up to $1.0 billion until and including May 6, 2027. Since the inception of the program through September\u00a030, 2026, 5,037,452 ADSs were repurchased at an average price of $91.98 (\u20ac80.10), for total consideration of $463.3\u00a0million (\u20ac403.5\u00a0million).<\/p>\n<p align=\"justify\">\u201cOur performance in the third quarter allowed us to narrow our full-year 2026 revenue guidance to the upper end of the previous guidance range,\u201d <b>said Ram\u00f3n Zapata, Chief Financial Officer at BioNTech<\/b>. \u201cFueled by our financial strength, we continue to focus our investments on our prioritized late-stage oncology programs. While we further enhance our operational efficiency and cost discipline, we return capital to shareholders through our share repurchase program. Together, these steps are aimed at creating sustainable long-term value.\u201d<\/p>\n<p align=\"justify\">\n        <b>Updated 2026 Financial Year Guidance<\/b><br \/>\n        <sup>6<\/sup><br \/>\n        <b>:<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:160.469px;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:422.406px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>FY 2026 non-IFRS Guidance<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:160.469px;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:203.328px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <b>Current<\/b><br \/>\n            <br \/>\n            <b>Nov. 3, 2026<\/b>\n          <\/td>\n<td style=\"width:219.078px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <b>Prior<\/b><br \/>\n            <br \/>\n            <b>Aug. 4, 2026<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:160.469px;border-bottom: solid black 1pt\">\n            <b>Revenues<\/b>\n          <\/td>\n<td style=\"width:203.328px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\u20ac1,700 \u2013 \u20ac1,900 million<\/td>\n<td style=\"width:219.078px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\u20ac1,600 \u2013 \u20ac1,900 million<\/td>\n<\/tr>\n<tr>\n<td style=\"width:160.469px;border-bottom: solid black 1pt\">\n            <b>Adjusted R&amp;D expenses<\/b>\n          <\/td>\n<td style=\"width:203.328px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">Unchanged<\/td>\n<td style=\"width:219.078px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\u20ac2,000 \u2013 \u20ac2,300 million<\/td>\n<\/tr>\n<tr>\n<td style=\"width:160.469px;border-bottom: solid black 1pt\">\n            <b>Adjusted SG&amp;A expenses<\/b><br \/>\n            <sup><br \/>\n              <b>3<\/b><br \/>\n            <\/sup>\n          <\/td>\n<td style=\"width:203.328px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">Unchanged<\/td>\n<td style=\"width:219.078px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\u20ac700 \u2013 \u20ac800 million<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">BioNTech is raising the midpoint of its previously provided full-year 2026 revenue guidance. The updated guidance follows the Company\u2019s revenue performance in the third quarter. The guidance for adjusted R&amp;D expenses as well as adjusted SG&amp;A expenses remains unchanged. <\/p>\n<p align=\"justify\">BioNTech exercised an option in the existing collaboration agreement with Roche\/Genentech where, under the terms of the agreement, future R&amp;D costs related to the program will be generally assigned to Roche\/Genentech effective January 1, 2027, while BioNTech will be eligible to receive royalties in case of successful development and commercialization.<\/p>\n<p align=\"justify\">The updated terms pursuant to the exercised option under the existing agreement align with BioNTech\u2019s broader capital allocation framework and will not affect the ongoing pancreatic ductal adenocarcinoma (\u201cPDAC\u201d) trial, which will continue as planned.<\/p>\n<p align=\"justify\">While this decision follows the regular assessment of the financial structure of existing collaborations, BioNTech\u2019s broader commitment to mRNA and its potential in oncology remains unchanged. Its conviction in mRNA is anchored by over a decade of translational and clinical research, as well as deep experience in the field. BioNTech continues to advance mRNA cancer immunotherapies and invest in them as a key pillar of its oncology strategy, including novel combination approaches intended to maximize the potential of its diversified oncology pipeline.<\/p>\n<p align=\"justify\">The full interim unaudited condensed consolidated financial statements can be found in BioNTech\u2019s Report on Form 6-K for the period ended September\u00a030, 2026, filed today with the United States Securities and Exchange Commission (\u201cSEC\u201d) and available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mPawQBNxgzuMSruNGzIHoQPy88KYAoWlungsLSnrDcKJXc4fE28pI2mCCZbcbBFX_t1X2k8Cm5uninReuu_2rA==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Endnotes<\/b><br \/>\n        <br \/>\n        <sup>1\u00a0 <\/sup>All numbers in this press release have been rounded. <br \/><sup>2<\/sup> In addition to BioNTech\u2019s results determined in accordance with International Financial Reporting Standards (\u201cIFRS\u201d), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of the Company\u2019s business performance (each referred to with the prefix \u201cAdjusted\u201d or, as a whole, \u201cAdjusted Results\u201d). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech\u2019s measures based on IFRS Accounting Standards and more information can be found at the end of this press release and in BioNTech\u2019s Report on Form 6-K for the period ended September\u00a030, 2026, filed on November\u00a03, 2026, which is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mPawQBNxgzuMSruNGzIHoebZbvUPaG9xJfP-oCYu1GcCzc9ByVi2fGNWzidxPtczCrRDkarOE61pZQEjoqxE5Q==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. The weighted average number of shares outstanding is excluded from that reconciliation. While non-IFRS measures may offer additional insights, BioNTech\u2019s non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside the Company\u2019s financial statements prepared in accordance with IFRS Accounting Standards. Unless otherwise indicated, Adjusted Results are identical to IFRS Results.<br \/><sup>3\u00a0 <\/sup>Sales, general and administrative expenses (\u201cSG&amp;A\u201d) include sales and marketing expenses as well as general and administrative expenses. Adjusted SG&amp;A expenses include adjusted sales and marketing expenses as well as adjusted general and administrative expenses.<br \/><sup>4\u00a0 <\/sup>As of September\u00a030, 2026.<br \/><sup>5 <\/sup>Only basic EPS are calculated in loss making periods. Diluted EPS include outstanding instruments from BioNTech\u2019s share-based payment programs. The weighted average number of shares outstanding is determined as described in BioNTech\u2019s Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended and is not adjusted by non-IFRS measures.<br \/><sup>6\u00a0 <\/sup>Excludes risks that are not yet known and\/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger &amp; Acquisitions (\u201cM&amp;A\u201d) transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech\u2019s Report on Form 6-K for the period ended September\u00a030, 2026, filed on November\u00a03, 2026, which is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mPawQBNxgzuMSruNGzIHoR2zaQVcKxtW05N6KEs3yfYRlyx-gAtJCnHLMU9HMlHmou-wfW-5CLJTIyUlpedA8A==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. <br \/><sup>7\u00a0 <\/sup>An overview of abbreviations of target structures and indications is compiled in a directory at the end of this press release.<\/p>\n<p align=\"justify\">\n        <b><br \/>\n          <i>Variant-adapted COVID-19 Vaccine<br \/><\/i><br \/>\n        <\/b>\u00a0<br \/>In the third quarter of 2026, BioNTech and Pfizer executed the commercial launch of their variant-adapted COVID-19 vaccine for the 2026\/2027 vaccination season.<\/p>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">In July 2026, BioNTech and Pfizer\u2019s monovalent XFG-adapted COVID-19 vaccine was approved by the European Commission following recommendation for marketing authorization by the European Medicines Agency\u2019s (\u201cEMA\u201d) Committee for Medicinal Products for Human Use (\u201cCHMP\u201d). The companies began shipments of the vaccine after approval to ensure rapid access of the season\u2019s vaccine.<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">In August 2026, the United States Food and Drug Administration (\u201cFDA\u201d) approved the supplemental Biologics License Application (\u201csBLA\u201d) for BioNTech and Pfizer\u2019s monovalent XFG-adapted COVID-19 vaccine for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. The new variant-adapted COVID-19 vaccine was shipped immediately following approval and was made available in pharmacies, hospitals, and clinics across the United States.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b><br \/>\n          <i>Select Oncology Pipeline Updates<\/p>\n<p><\/i><br \/>\n        <\/b><br \/>\n        <br \/>\n        <i>Next-Generation Immunomodulators and Combinations<\/p>\n<p><\/i><br \/>\n        <br \/>\n        <b>Pumitamig (BNT327\/BMS986545)<\/b> is an investigational bispecific immunomodulator combining PD-L1<sup>7<\/sup> checkpoint inhibition with VEGF-A neutralization that is being developed in collaboration with Bristol Myers Squibb Company (\u201cBMS\u201d).<\/p>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">Pumitamig is currently being evaluated in seven pivotal trials across the ROSETTA clinical development program, with five new global clinical trials initiated in 2026 spanning triple-negative breast cancer (\u201cTNBC\u201d), colorectal cancer (\u201cCRC\u201d), gastric cancer, and non-small cell lung cancer (\u201cNSCLC\u201d), including two clinical trials in patients with unresectable stage III NSCLC, advanced disease and high PD-L1 expression (TPS \u226550%), respectively.<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">A global Phase 2 clinical trial (ROSETTA Lung-107; <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06841055?cond=NCT06841055&amp;viewType=Card&amp;rank=1\" rel=\"nofollow\" target=\"_blank\">NCT06841055<\/a>) is being conducted to evaluate pumitamig in combination with docetaxel as a second-line treatment for patients with NSCLC. In October 2026, data from this trial were presented at the European Society for Medical Oncology (\u201cESMO\u201d) Congress 2026. Pumitamig in combination with docetaxel showed encouraging antitumor activity with a manageable safety profile in patients with metastatic NSCLC post-chemoimmunotherapy. These data extend evidence for pumitamig\u2019s NSCLC development program into the second-line setting where there remains high unmet medical need, representing the third global Phase 2 dataset in lung cancer.<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">Global Phase 2 clinical trials (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06449209?cond=NCT06449209&amp;viewType=Card&amp;rank=1\" rel=\"nofollow\" target=\"_blank\">NCT06449209<\/a> and <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06449222\" rel=\"nofollow\" target=\"_blank\">NCT06449222<\/a>) are being conducted to evaluate pumitamig in combination with chemotherapy in patients with untreated extensive-stage small cell lung cancer (\u201cES-SCLC\u201d) and in patients with small cell lung cancer (\u201cSCLC\u201d) that progressed after first- or second-line treatment and as a first- and second-line treatment for patients with locally advanced or metastatic TNBC, respectively. In October 2026, data from a subgroup analysis in patients with brain metastases from these trials were presented at the ESMO Congress 2026. Patients with TNBC or SCLC and brain metastases at baseline benefited clinically from pumitamig plus chemotherapy both systemically and intracranially, supporting pumitamig\u2019s potential across difficult-to-treat tumor types and patient populations. <\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">BioNTech entered into a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (\u201cGilead\u201d) to evaluate pumitamig in combination with the TROP2-directed ADC sacituzumab govitecan as first-line treatment for patients with PD-L1 low or negative locally advanced or metastatic TNBC in the ROSETTA Breast-01 trial. Pending regulatory approval, this will be the first global Phase 3 clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07173751\" rel=\"nofollow\" target=\"_blank\">NCT07173751<\/a>) of pumitamig in combination with an ADC, reflecting the evolving standard of care in 1L TNBC.<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">Pumitamig is also being evaluated in additional solid tumor indications, including first-line hepatocellular carcinoma (\u201cHCC\u201d), second-line glioblastoma (\u201cGBM\u201d), first-line PDAC and first-line renal cell carcinoma (\u201cRCC\u201d) in various Phase 1\/2 and Phase 2 trials, both as monotherapy and in combination with standard of care.<\/li>\n<\/ul>\n<p align=\"justify\">BioNTech has several signal-seeking clinical trials ongoing evaluating pumitamig with the Company\u2019s proprietary assets:<\/p>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">A Phase 2 clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06953089?cond=NCT06953089&amp;viewType=Card&amp;rank=1\" rel=\"nofollow\" target=\"_blank\">NCT06953089<\/a>) is being conducted to evaluate elfetabart drozuntecan (BNT324\/DB-1311) in combination with pumitamig. In October 2026, data from this trial were presented at the ESMO Congress 2026. Elfetabart drozuntecan in combination with pumitamig was well tolerated and encouraging antitumor activity was observed in patients across multiple tumor types. These data support the potential of pumitamig as a backbone in novel treatment combinations, furthering BioNTech\u2019s combination strategy across multiple tumor types with high unmet medical need. They also help build the body of evidence for pumitamig in combination with ADCs that will inform potential registrational trials.<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">A Phase 1\/2 clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06892548?cond=NCT06892548&amp;viewType=Card&amp;rank=1\" rel=\"nofollow\" target=\"_blank\">NCT06892548<\/a>) is being conducted to evaluate elfetabart drozuntecan (BNT324\/DB-1311) in combination with pumitamig in patients with advanced lung cancers. In September 2026, data from this trial were presented at the IASLC 2026 World Conference on Lung Cancer (\u201cWCLC\u201d). Elfetabart drozuntecan in combination with pumitamig showed encouraging early efficacy and a manageable safety profile in SCLC, across lines of therapy and dose levels. These were the first data in lung cancer for any investigational PD-(L)1xVEGF bispecific immunomodulator combined with an ADC candidate, underscoring BioNTech\u2019s leadership in developing novel-novel combination treatment strategies.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Gotistobart<\/b><br \/>\n        <b> (BNT316\/ONC-392)<\/b> is a tumor microenvironment-selective regulatory T cell depletion candidate that targets CTLA-4 and is being developed in collaboration with OncoC4, Inc. (\u201cOncoC4\u201d).\u00a0<\/p>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">A global Phase 3 clinical trial (PRESERVE-003; <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05671510\" rel=\"nofollow\" target=\"_blank\">NCT05671510<\/a>) is ongoing to evaluate the efficacy and safety of gotistobart as monotherapy in patients with metastatic squamous NSCLC that progressed on previous platinum-based chemotherapy and PD-(L)1-inhibitor treatment. <\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">In September 2026, updated data from the stage 1 of this trial were presented at WCLC. Data demonstrated that gotistobart nearly doubled median overall survival (\u201cOS\u201d) versus chemotherapy in patients with squamous NSCLC who had progressed on PD-(L)1 inhibitors.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">Gotistobart continues to show potential as a chemotherapy-free monotherapy in a hard-to-treat lung cancer setting.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">Based on current event accrual projections, the first interim analysis from stage 2 of the Phase 3 clinical trial is expected in 2026. This will be assessed by the Independent Data Monitoring Committee (\u201cIDMC\u201d) to recommend whether to unblind the trial or continue to the next pre-planned interim analysis.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n        <i>Antibody-Drug Conjugates <\/i>\n      <\/p>\n<p align=\"justify\">\n        <b>Trastuzumab pamirtecan<\/b> (BNT323\/DB-1303) is an ADC candidate targeting HER2 that is being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. (\u201cDualityBio\u201d).\u00a0<\/p>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">Trastuzumab pamirtecan is being evaluated in two Phase 3 clinical trials in HR-positive, HER2-low metastatic breast cancer (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06018337\" rel=\"nofollow\" target=\"_blank\">NCT06018337<\/a>) and HER2-expressing endometrial cancer (\u201cEC\u201d) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06340568\" rel=\"nofollow\" target=\"_blank\">NCT06340568<\/a>).<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">The global Phase 3 clinical trial DYNASTY-Breast02 (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06018337\" rel=\"nofollow\" target=\"_blank\">NCT06018337<\/a>) to evaluate trastuzumab pamirtecan in patients with HR-positive, HER2-low metastatic breast cancer met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (\u201cPFS\u201d) compared to investigator\u2019s choice of chemotherapy. At this interim analysis for the secondary endpoint of OS, data were not mature. A higher rate of interstitial lung disease (\u201cILD\u201d) was reported in this trial compared to prior trials with trastuzumab pamirtecan, with most cases being Grade 1 and 2. Severe and fatal events were reported in a small proportion of patients (Grade 3 to 5). Otherwise, the overall safety profile was consistent with prior clinical trials and no new safety signals were observed.<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">The available efficacy and safety data, as of this data cut-off date, suggest that the potential benefit to patients would be limited in the context of the HR+\/HER2-low metastatic breast cancer treatment landscape. <\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">BioNTech and DualityBio are currently discussing the totality of clinical data for trastuzumab pamirtecan across endometrial and breast cancer, within the context of the evolving treatment landscape, and areas of unmet medical need, and will determine the next steps.<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">As part of this, BioNTech and DualityBio are discussing plans for a BLA submission and will update the markets accordingly.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <i>mRNA Cancer Immunotherapies<\/i>\n      <\/p>\n<p align=\"justify\">\n        <b>Autogene cevumeran<\/b> (BNT122\/RO7198457) is an mRNA cancer immunotherapy candidate for individualized neoantigen-specific immunotherapy (\u201ciNeST\u201d) that is being developed in collaboration with Genentech, Inc. (\u201cGenentech\u201d), a member of the Roche Group (\u201cRoche\u201d).<\/p>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">Early termination was initiated in a randomized Phase 2 clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04486378\" rel=\"nofollow\" target=\"_blank\">NCT04486378<\/a>) to evaluate autogene cevumeran as an adjuvant treatment of circulating tumor DNA, or ctDNA, positive, surgically resected Stage II (high risk)\/Stage III CRC compared to watchful waiting after surgery and chemotherapy, which is the current standard of care for these high-risk patients.<\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">The Phase 2 clinical trial IMcode003 (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05968326\" rel=\"nofollow\" target=\"_blank\">NCT05968326<\/a>) evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy in adjuvant PDAC is not affected and continues as planned. In August 2026, the trial completed enrollment.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>BNT113 <\/b>is an mRNA cancer immunotherapy candidate and based on BioNTech\u2019s fully owned, off-the-shelf FixVac platform, encoding the two oncoproteins E6 and E7 that are frequently found in human papillomavirus type 16 positive (\u201cHPV16+\u201d) solid tumors.<\/p>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">In October 2026, the first topline results from the AHEAD-MERIT Phase 2\/3 clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04534205\" rel=\"nofollow\" target=\"_blank\">NCT04534205<\/a>) were announced. The Phase 3 part of AHEAD-MERIT has dual primary endpoints, PFS and OS, providing complementary measures of clinical benefit. At the analysis for PFS, BNT113 in combination with pembrolizumab did not demonstrate a statistically significant improvement in PFS versus pembrolizumab alone. The IDMC has recommended that the clinical trial continues as planned to evaluate the second primary endpoint of OS to complete the assessment of the potential of this approach to help patients live longer. As immune-mediated anti-tumor effects build and deepen over time, the analysis of the second dual primary endpoint, OS, will be critical to fully assess the potential of this approach. Under the trial\u2019s pre-specified statistical design, a statistically significant improvement in OS would establish a positive trial outcome, even if the PFS dual primary endpoint was not met. BioNTech remains blinded to ongoing trial data in accordance with the trial\u2019s governance procedures.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Upcoming Investor and Analyst Events<\/b>\u00a0<\/p>\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">BioNTech Fourth Quarter and Full Year 2026 Financial Results and Corporate Update: March 2, 2027<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Conference Call and Webcast Information<\/b>\n      <\/p>\n<p align=\"justify\">BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November\u00a03, 2026, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial results and provide a corporate update for the third quarter of 2026.<\/p>\n<p align=\"justify\">To access the live conference call via telephone, please register <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TpI225v6WT1nTkr9kFr6qF16g0Sbeps4Vl_aFdIx5TAfoufNXD4ipEKY1_gi6Exx7rZ4rvBUY_cgHNPm-ih95eF7nzelNO3eU5fcreKBAfxgucNK6JekpuiboezkPfzcZxwoKcY364fskZasyrzcTGzc8onVQFTeW9oLCZrwzsA=\" rel=\"nofollow\" target=\"_blank\">via this link<\/a>. Once registered, dial-in numbers and a PIN number will be provided.<\/p>\n<p align=\"justify\">The slide presentation and audio of the webcast will be available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TpI225v6WT1nTkr9kFr6qK3CKmRGGd5lxYW0ojqzHAm9GF1kRLFvMDfp1mFQfy0I_lk1xeLdtruV4pk5ewGatpjcTfTfd-v6-ITLhCQjfChaL2mdrWPwccwj0yAzh2yn\" rel=\"nofollow\" target=\"_blank\">via this link<\/a>.<\/p>\n<p align=\"justify\">Participants may also access the slides and the webcast of the conference call via the \u201cEvents &amp; Presentations\u201d page of the Investor section of the Company\u2019s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the closing of the call and archived on the Company\u2019s website for 30 days following the call.<\/p>\n<p align=\"justify\">\n        <b>About BioNTech<\/b><br \/>\n        <br \/>BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.<\/p>\n<p>For more information, please visit www.BioNTech.com.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech\u2019s expected revenues and net profit\/(loss) related to sales of BioNTech\u2019s COVID-19 vaccine in territories controlled by BioNTech\u2019s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech\u2019s partners; the rate and degree of market acceptance of BioNTech\u2019s COVID-19 vaccine and, if approved, BioNTech\u2019s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech\u2019s research and development programs, including BioNTech\u2019s current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or clinical trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech\u2019s expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational clinical trials, and the registrational potential of any clinical trial BioNTech may initiate; BioNTech\u2019s expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech\u2019s expectations with respect to intellectual property; the impact of BioNTech\u2019s collaboration and licensing agreements; BioNTech\u2019s expectations with respect to developments in law, public policy, and international trade; BioNTech\u2019s estimates of revenues, research and development expenses, selling, general and administrative expenses and capital expenditures for operating activities; BioNTech\u2019s expectations for upcoming scientific and investor presentations; and BioNTech\u2019s expectations of net profit\/(loss). In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.<\/p>\n<p align=\"justify\">The forward-looking statements in this press release are based on BioNTech\u2019s current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech\u2019s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and\/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and\/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech\u2019s pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors;\u00a0the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech\u2019s other product candidates; the timing of and BioNTech\u2019s ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech\u2019s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech\u2019s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech\u2019s third-party collaborators to continue research and development activities relating to BioNTech&#8217;s development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech\u2019s and its collaborators\u2019 ability to commercialize and market its product candidates, if approved; BioNTech\u2019s ability to manage its development and related expenses; regulatory and political developments; BioNTech\u2019s ability to effectively scale its production capabilities and manufacture its products and product candidates; expected changes to BioNTech\u2019s leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. <\/p>\n<p align=\"justify\">You should review the risks and uncertainties described under the heading \u201cRisk Factors\u201d in BioNTech\u2019s Report on Form 6-K for the period ended September\u00a030, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mPawQBNxgzuMSruNGzIHoTxfPP3X8_ftnh8HcXdTJMPvmZgiaOhBOvFB3E1MF29jvz30Gwiul53xyIbugxfPJUsdC337J3OT9ykINwR4p4x0tBRNX9E2LA9973nWj8AnNWNF5cnzsOTUCPBOnm6KXfIxMUDm6JNuLkjkxTqIDaRxG18Dk0AWBK5R2oL8iJEgdQ8BQsgcwK3dHYvv3DwX6snFFTaxdhXZI7ZIxlpRSba9PPH57n82UqGmzOpTMXKJ\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.<\/p>\n<p align=\"justify\">\n        <b>CONTACTS<\/b>\n      <\/p>\n<p>\n        <b>Investor Relations<\/b><br \/>\n        <br \/>Douglas Maffei, PhD<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BHvUAtmK5RlLwl7cSqKG_PlaMZsJgzIHnAjo3uaWOtqWzWO_YA0gseZJjXx5vNhGVeJ1X9byBv4TSJ4L0hF7CGUmfH_nYTJxNlgcf_JwfbA=\" rel=\"nofollow\" target=\"_blank\">Investors@biontech.de<\/a><\/p>\n<p>\n        <b>Media Relations<br \/><\/b>Jasmina Alatovic<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FYNzgkR1efq6f6eObSsFZVYtoJ96YNDy98Rwe0N7JM24stlh7eKPNB1qPp42ynJv4FXCHJpN2zefPvyMGAW7Zpm3lBSyoyKu7M0nCd_GfdlUhdu5K7-gfwyVfFJmI7QkjQF32agdoHlDudP-gnn3KtEB2BQto28siqvU88m3NQE72YAX2N5kXnMAQV49pVXU6eLqAsJ0cnzos06bF065DiHV8MRy2mORxJuSWH8EzBKYLqSj6Nf8_c587QpAC4iCINlTOUIaKIYUr7v6Y5mVpQ==\" rel=\"nofollow\" target=\"_blank\">Media@biontech.de<\/a><\/p>\n<p>\n        <b>Abbreviation Overview<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ADC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Antibody-drug conjugate<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">BLA<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Biologics license application<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">CRC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Colorectal cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ctDNA<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Circulating tumor DNA<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">CTLA-4<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Cytotoxic T-lymphocyte-associated protein 4<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">EC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Endometrial cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ES-SCLC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Extensive-stage small cell lung cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">GBM<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Glioblastoma<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">HCC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Hepatocellular carcinoma<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">HER2<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Human epidermal growth factor receptor 2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">HPV16+<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Human papillomavirus type 16 positive<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">HR<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Hormone receptor<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">IDMC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Independent Data Monitoring Committee<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ILD<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Interstitial lung disease<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">iNeST<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Individualized neoantigen-specific immunotherapy<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">IO<\/td>\n<td style=\"width:374px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Immuno-oncology<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">mRNA<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Messenger ribonucleic acid<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">NSCLC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Non-small cell lung cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">OS<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Overall survival<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">PDAC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Pancreatic ductal adenocarcinoma<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">PD-(L)1<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Programmed cell death protein (death-ligand) 1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">PFS<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Progression-free survival<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">RCC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Renal cell carcinoma<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">SCLC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Small cell lung cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">TPS<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Tumor Proportion Score<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">TNBC<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Triple-negative breast cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">TROP2<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Trophoblast cell surface antigen 2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">VEGF-A<\/td>\n<td style=\"width:374px;text-align: justify;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Vascular endothelial growth factor A<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<p align=\"center\">\n        <b><br \/>\n          <br \/>Interim Condensed Consolidated Statements of Profit or Loss<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:261px\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td colspan=\"2\" style=\"width:170px;text-align: center;vertical-align: middle\">\n            <b>Three months ended September 30,<\/b>\n          <\/td>\n<td colspan=\"2\" style=\"width:170px;text-align: center;vertical-align: middle\">\n            <b>Nine months ended September 30,<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px\">\u00a0<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle\">\n            <b>2026<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle\">\n            <b>2025<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle\">\n            <b>2026<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle\">\n            <b>2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px\">\n            <i>(in millions \u20ac, except per share data)<\/i>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Revenues<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,289.2<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,518.9<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,512.9<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,962.5<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Cost of sales<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(103.3)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(148.3)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(271.7)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(308.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Research and development expenses<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(748.1)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(564.8)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,856.1)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,599.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Sales and marketing expenses<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(43.3)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(27.3)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(111.3)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(60.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">General and administrative expenses<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(135.2)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(121.2)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(415.8)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(345.8)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Other operating expenses<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(163.6)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(729.5)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(443.7)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(884.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Other operating income<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">29.3<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">25.3<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">85.1<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">154.6<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">\n            <b>Operating profit \/ (loss)<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>125.0<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(46.9)<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,500.6)<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,082.1)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Finance income<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">105.3<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">96.8<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">323.2<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">324.8<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Finance expenses<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(8.3)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(25.2)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(27.4)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(66.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">\n            <b>Profit \/ (Loss) before tax<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>222.0<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>24.7<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,204.8)<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(823.4)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Income taxes<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(37.5)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(53.4)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">36.6<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(7.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">\n            <b>Net profit \/ (loss)<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>184.5<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(28.7)<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,168.2)<\/b>\n          <\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(831.1)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">\n            <b>Earnings \/ (Loss) per share<\/b>\n          <\/td>\n<td style=\"width:85px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:85px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:85px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:85px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Basic profit \/ (loss) per share<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">0.74<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(0.12)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(4.63)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(3.45)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:261px;border-bottom: solid black 1pt\">Diluted profit \/ (loss) per share<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">0.73<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(0.12)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(4.63)<\/td>\n<td style=\"width:85px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(3.45)<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <b><br \/>\n          <br \/>Interim Condensed Consolidated Statements of Financial Position<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:411px\">\u00a0<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle\">\n            <b>September 30<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle\">\n            <b>December\u00a031,<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px\">\n            <i>(in millions \u20ac)<\/i>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle\">\n            <b>2026<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle\">\n            <b>2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Assets<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\n            <i>\u00a0<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Non-current assets <\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Goodwill<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">376.0<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">367.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other intangible assets<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,201.6<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,606.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Property, plant and equipment <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,000.9<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,080.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Right-of-use assets<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">159.2<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">210.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Contract assets <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other financial assets<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,727.3<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2,554.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other assets<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">15.0<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">7.3<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Deferred tax assets <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">20.0<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">13.5<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Total non-current assets<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>4,500.0<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>5,842.0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Current assets<\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Inventories<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">64.9<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">110.7<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Trade and other receivables<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">666.3<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">924.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Contract assets <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">5.4<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">8.1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other financial assets <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">4,457.6<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">7,201.8<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other assets<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">145.2<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">173.8<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Income tax assets <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">124.3<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">52.6<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Cash and cash equivalents<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">10,200.8<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">7,675.4<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Assets held for sale<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">9.3<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Total current assets<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>15,673.8<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>16,146.6<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Total assets<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>20,173.8<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>21,988.6<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Equity and liabilities<\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Equity<\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Share capital<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">259.0<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">259.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Capital reserve<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2,076.5<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2,473.3<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Treasury shares<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(11.1)<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(7.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Retained earnings<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">16,793.7<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">17,961.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other reserves <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,406.4)<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,462.3)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Total equity<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>17,711.7<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>19,224.2<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Non-current liabilities<\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Lease liabilities, loans and borrowings<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">255.4<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">215.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other financial liabilities<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">108.9<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">94.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Provisions<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">64.6<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">35.5<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Contract liabilities<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">0.7<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">88.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other liabilities<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">117.1<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">104.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Deferred tax liabilities<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">82.6<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">84.3<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Total non-current liabilities <\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>629.3<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>622.1<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Current liabilities<\/b>\n          <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Lease liabilities, loans and borrowings<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">104.4<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">52.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Trade payables and other payables<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">523.1<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">534.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other financial liabilities<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">141.2<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">351.7<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Income tax liabilities<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">13.2<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">65.6<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Provisions<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">244.2<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">145.3<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Contract liabilities<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">623.6<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">754.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Other liabilities<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">181.1<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">237.7<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">Liabilities related to assets held for sale<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2.0<\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Total current liabilities<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>1,832.8<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>2,142.3<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Total liabilities <\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>2,462.1<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>2,764.4<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:411px;border-bottom: solid black 1pt\">\n            <b>Total equity and liabilities <\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>20,173.8<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>21,988.6<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <b><br \/>\n          <br \/>Interim Condensed Consolidated Statements of Cash Flows<\/b><br \/>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:357px\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:122px;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle\">\n            <b>Three months ended <\/b><br \/>\n            <br \/>\n            <b>September 30,<\/b>\n          <\/td>\n<td colspan=\"2\" style=\"width:122px;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle\">\n            <b>Nine months ended <\/b><br \/>\n            <br \/>\n            <b>September 30,<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px\">\u00a0<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle\">\n            <b>2026<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle\">\n            <b>2025<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle\">\n            <b>2026<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle\">\n            <b>2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <i>(in millions \u20ac)<\/i>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Operating activities<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Net profit \/ (loss)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">184.5<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(28.7)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,168.2)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(831.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Income taxes<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">37.5<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">53.4<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(36.6)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">7.7<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Profit \/ (Loss) before tax<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>222.0<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>24.7<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,204.8)<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(823.4)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Adjustments to reconcile profit \/ (loss) before tax to net cash flows: <\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">332.3<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">124.2<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">719.7<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">218.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Share-based payment expenses<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">20.0<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">27.9<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">63.7<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">82.1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Net foreign exchange differences<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(3.2)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(24.1)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">14.3<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">36.4<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Gain on disposal of property, plant and equipment<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(0.1)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1.3)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1.1)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Finance income excluding foreign exchange differences<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(96.3)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(96.8)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(301.9)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(324.8)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Finance expense excluding foreign exchange differences<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">8.3<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2.6<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">27.4<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">17.1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Government and similar grants<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(13.2)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(10.5)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(45.3)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(43.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Other non-cash income<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(15.0)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Working capital adjustments:<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Decrease \/ (Increase) in trade and other receivables, contract assets and other assets<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(489.1)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">897.1<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">308.1<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,005.5<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Decrease in inventories<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">33.5<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">5.1<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">43.7<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">61.7<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">Decrease in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(197.6)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(242.5)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(344.8)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(314.9)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Interest received and realized gains from cash and cash equivalents<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">78.0<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">83.5<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">235.4<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">275.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Interest paid and realized losses from cash and cash equivalents<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(2.8)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(2.4)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(8.4)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(8.2)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Income tax paid, net<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(33.7)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(9.6)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(91.4)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(36.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Share-based payments<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(4.2)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(4.2)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(19.2)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(19.3)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Government and similar grants received<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">16.3<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">7.0<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">64.3<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">38.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Net cash flows from \/ (used in) operating activities<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(129.8)<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>780.7<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(540.3)<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>146.5<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Investing activities<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Purchase of property, plant and equipment<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(33.6)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(35.9)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(145.0)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(111.9)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Proceeds from sale of property, plant and equipment<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1.5<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2.9<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">6.5<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">3.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Purchase of intangible assets<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(14.9)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(2.7)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(37.8)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(575.0)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Acquisition of subsidiaries and businesses, net of cash acquired<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(31.8)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(31.8)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(78.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Investment in other financial assets<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,504.9)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(2,869.0)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(5,111.0)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(7,046.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Proceeds from maturity of other financial assets<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2,391.4<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1,979.4<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">8,677.3<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">8,065.3<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Net cash flows from \/ (used in) investing activities<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>807.7<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(925.3)<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>3,358.2<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>257.1<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Financing activities<\/b>\n          <\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:61px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Proceeds from loans and borrowings<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">52.9<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">129.1<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Repayment of loans and borrowings<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1.2)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(5.9)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(9.4)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Payments related to lease liabilities<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(11.2)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(10.3)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(34.4)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(29.2)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Share repurchase program<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(274.3)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(403.5)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Net cash flows used in financing activities<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(232.6)<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(11.5)<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(314.7)<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(38.6)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Net increase \/ (decrease) in cash and cash equivalents<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">445.3<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(156.1)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2,503.2<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">365.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Change in cash and cash equivalents resulting from exchange rate differences<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">2.0<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(21.5)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(4.7)<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(28.4)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Change in cash and cash equivalents resulting from other valuation effects<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">12.5<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1.0<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">26.9<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(5.6)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">Cash and cash equivalents at the beginning of the period<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">9,741.0<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">10,269.5<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">7,675.4<\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">9,761.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:357px;border-bottom: solid black 1pt\">\n            <b>Cash and cash equivalents as of September 30<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>10,200.8<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>10,092.9<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>10,200.8<\/b>\n          <\/td>\n<td style=\"width:61px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>10,092.9<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p>Certain prior period lines were aggregated to conform to current period presentation and to improve readability.<\/p>\n<p align=\"center\">\n        <b>Non-IFRS Reconciliation<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"7\" style=\"width:581px\">\n            <b>Non-IFRS Reconciliation for the three months ended September 30, 2026<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:62.6406px;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:279.422px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>non-IFRS adjustments (unaudited)<\/b>\n          <\/td>\n<td style=\"width:62.6875px;vertical-align: bottom\">\n            <i>\u00a0<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"width:176.25px;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <i>(in millions \u20ac, except per share data)<\/i>\n          <\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;vertical-align: bottom;text-align: right;vertical-align: middle\">\n            <b>IFRS <\/b><br \/>\n            <br \/>\n            <b>Results<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:66.9062px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Expenses and income from legal proceedings<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:65.7969px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Impairment and reversal<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:67.4688px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Employee-related expenses from restructuring<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:79.25px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Income from bargain purchase and income and expenses from divestiture related items<\/b>\n          <\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;vertical-align: bottom;text-align: right;vertical-align: middle\">\n            <b>Adjusted <\/b><br \/>\n            <br \/>\n            <b>Results<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">Cost of sales<\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(103.3)<\/td>\n<td style=\"width:66.9062px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:65.7969px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">11.4<\/td>\n<td style=\"width:67.4688px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:79.25px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(91.9)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">Research and development expenses<\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(748.1)<\/td>\n<td style=\"width:66.9062px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:65.7969px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">169.6<\/td>\n<td style=\"width:67.4688px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:79.25px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(578.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">Other operating expenses<\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(163.6)<\/td>\n<td style=\"width:66.9062px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">13.5<\/td>\n<td style=\"width:65.7969px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">42.2<\/td>\n<td style=\"width:67.4688px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">19.7<\/td>\n<td style=\"width:79.25px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(88.2)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">\n            <b>Operating profit<\/b>\n          <\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>125.0<\/b>\n          <\/td>\n<td style=\"width:66.9062px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>13.5<\/b>\n          <\/td>\n<td style=\"width:65.7969px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>223.2<\/b>\n          <\/td>\n<td style=\"width:67.4688px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>19.7<\/b>\n          <\/td>\n<td style=\"width:79.25px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>381.4<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">\n            <b>Profit before tax<\/b>\n          <\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>222.0<\/b>\n          <\/td>\n<td style=\"width:66.9062px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>13.5<\/b>\n          <\/td>\n<td style=\"width:65.7969px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>223.2<\/b>\n          <\/td>\n<td style=\"width:67.4688px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>19.7<\/b>\n          <\/td>\n<td style=\"width:79.25px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>478.4<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">\n            <b>Net profit<\/b><br \/>\n            <sup><br \/>\n              <b>1<\/b><br \/>\n            <\/sup>\n          <\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>184.5<\/b>\n          <\/td>\n<td style=\"width:66.9062px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>13.5<\/b>\n          <\/td>\n<td style=\"width:65.7969px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>223.2<\/b>\n          <\/td>\n<td style=\"width:67.4688px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>19.7<\/b>\n          <\/td>\n<td style=\"width:79.25px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>440.9<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">\n            <b>Earnings per share<\/b>\n          <\/td>\n<td style=\"width:62.6406px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66.9062px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:65.7969px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:67.4688px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:79.25px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:62.6875px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">Basic profit per share<\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">0.74<\/td>\n<td style=\"width:66.9062px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:65.7969px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:67.4688px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:79.25px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1.76<\/td>\n<\/tr>\n<tr>\n<td style=\"width:176.25px;border-bottom: solid black 1pt\">Diluted profit per share<\/td>\n<td style=\"width:62.6406px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">0.73<\/td>\n<td style=\"width:66.9062px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:65.7969px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:67.4688px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:79.25px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:62.6875px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">1.76<\/td>\n<\/tr>\n<\/table>\n<p>\n        <sup>1<\/sup> Tax effects are not considered as part of BioNTech&#8217;s non-IFRS adjustments.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"7\" style=\"width:601px\">\n            <b>Non-IFRS Reconciliation for the three months ended September 30, 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:285px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>non-IFRS adjustments (unaudited)<\/b>\n          <\/td>\n<td style=\"width:56px;vertical-align: bottom\">\n            <i>\u00a0<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"width:201px;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <i>(in millions \u20ac, except per share data)<\/i>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom;text-align: right;vertical-align: middle\">\n            <b>IFRS <\/b><br \/>\n            <br \/>\n            <b>Results<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Expenses and income from legal proceedings<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Impairment and reversal<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Employee-related expenses from restructuring<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <b>Income from bargain purchase and income and expenses from divestiture related items<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;vertical-align: bottom;text-align: right;vertical-align: middle\">\n            <b>Adjusted <\/b><br \/>\n            <br \/>\n            <b>Results<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:59px;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:56px;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Research and development expenses<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(564.8)<\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">85.4<\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(479.4)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Other operating expenses<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(729.5)<\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">678.5<\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">17.3<\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(33.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Operating profit \/ (loss)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(46.9)<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>678.5<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>85.4<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>17.3<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>734.3<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Profit before tax<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>24.7<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>678.5<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>85.4<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>17.3<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>805.9<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Net profit \/ (loss)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(28.7)<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>678.5<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>85.4<\/b>\n          <\/td>\n<td style=\"width:67px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>17.3<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>752.5<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Earnings \/ (Loss) per share<\/b>\n          <\/td>\n<td style=\"width:59px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:84px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:56px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Basic profit \/ (loss) per share<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(0.12)<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:84px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">3.12<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Diluted profit \/ (loss) per share<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(0.12)<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:67px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:84px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">3.11<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <sup>1<\/sup> Tax effects are not considered as part of BioNTech&#8217;s non-IFRS adjustments.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"7\" style=\"width:601px\">\n            <b>Non-IFRS Reconciliation for the nine months ended September 30, 2026<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:282px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>non-IFRS adjustments (unaudited)<\/b>\n          <\/td>\n<td style=\"width:59px;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"width:201px;vertical-align: bottom\">\n            <i>(in millions \u20ac, except per share data)<\/i>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom;text-align: right;vertical-align: middle\">\n            <b>IFRS <\/b><br \/>\n            <br \/>\n            <b>Results<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:66px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>Expenses and income from legal proceedings<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:66px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>Impairment and reversal<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:66px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>Employee-related expenses from restructuring<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:84px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>Income from bargain purchase and income and expenses from divestiture related items<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom;text-align: right;vertical-align: middle\">\n            <b>Adjusted <\/b><br \/>\n            <br \/>\n            <b>Results<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Cost of sales<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(271.7)<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">11.4<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(260.3)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Research and development expenses<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,856.1)<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">273.4<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,582.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Other operating expenses<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(443.7)<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">13.5<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">129.2<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">124.8<\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(176.2)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Operating loss<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,500.6)<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>13.5<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>414.0<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>124.8<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(948.3)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Loss before tax<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,204.8)<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>13.5<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>414.0<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>124.8<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(652.5)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Net loss<\/b><br \/>\n            <sup><br \/>\n              <b>1<\/b><br \/>\n            <\/sup>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,168.2)<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>13.5<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>414.0<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>124.8<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(615.9)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Loss per share<\/b>\n          <\/td>\n<td style=\"width:59px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:84px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Basic and diluted loss per share<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(4.63)<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:84px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(2.44)<\/td>\n<\/tr>\n<\/table>\n<p>\n        <sup>1<\/sup> Tax effects are not considered as part of BioNTech&#8217;s non-IFRS adjustments.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"7\" style=\"width:601px\">\n            <b>Non-IFRS Reconciliation for the nine months ended September 30, 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:282px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>non-IFRS adjustments (unaudited)<\/b>\n          <\/td>\n<td style=\"width:59px;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"width:201px;vertical-align: bottom\">\n            <i>(in millions \u20ac, except per share data)<\/i>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom;text-align: right;vertical-align: middle\">\n            <b>IFRS <\/b><br \/>\n            <br \/>\n            <b>Results<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:66px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>Expenses and income from legal proceedings<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:66px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>Impairment and reversal<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:66px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>Employee-related expenses from restructuring<\/b>\n          <\/td>\n<td rowspan=\"2\" style=\"width:84px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>Income from bargain purchase and income and expenses from divestiture related items<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom;text-align: right;vertical-align: middle\">\n            <b>Adjusted <\/b><br \/>\n            <br \/>\n            <b>Results<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Research and development expenses<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,599.5)<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">85.4<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(1,514.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Other operating expenses<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(884.7)<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">678.5<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">10.0<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">45.1<\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(151.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Other operating income<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">154.6<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\u2014<\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(15.0)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">139.6<\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Operating loss<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(1,082.1)<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>678.5<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>95.4<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>45.1<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(15.0)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(278.1)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Loss before tax<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(823.4)<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>678.5<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>95.4<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>45.1<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(15.0)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(19.4)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Net loss<\/b><br \/>\n            <sup><br \/>\n              <b>1<\/b><br \/>\n            <\/sup>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(831.1)<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>678.5<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>95.4<\/b>\n          <\/td>\n<td style=\"width:66px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>45.1<\/b>\n          <\/td>\n<td style=\"width:84px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(15.0)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">\n            <b>(27.1)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">\n            <b>Loss per share<\/b>\n          <\/td>\n<td style=\"width:59px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:84px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;border-bottom: solid black 1pt\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:201px;border-bottom: solid black 1pt\">Basic and diluted loss per share<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(3.45)<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:66px;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:84px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt\">(0.11)<\/td>\n<\/tr>\n<\/table>\n<p>\n        <sup>1<\/sup> Tax effects are not considered as part of BioNTech&#8217;s non-IFRS adjustments.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MDlmYzE5ZjAtMzgxNS00MzUwLTg0MTAtYWI4MDYyNmJlZGQyLTEwMTI1NTgtMjAyNi0xMS0wMy1lbg==\/tiny\/BioNTech-SE.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead\u2019s TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer Launched variant-adapted COVID-19 vaccine for the 2026\/2027 vaccination season in multiple regions worldwide Third quarter 2026 revenues of \u20ac1,289.2\u00a0million1 , adjusted2 R&amp;D expenses of \u20ac578.5\u00a0million (IFRS R&amp;D expenses of \u20ac748.1\u00a0million), and adjusted SG&amp;A3 expenses of \u20ac178.5\u00a0million Raised full-year 2026 revenue guidance midpoint and updated range to \u20ac1.7\u20131.9 billion, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016616","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead\u2019s TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer Launched variant-adapted COVID-19 vaccine for the 2026\/2027 vaccination season in multiple regions worldwide Third quarter 2026 revenues of \u20ac1,289.2\u00a0million1 , adjusted2 R&amp;D expenses of \u20ac578.5\u00a0million (IFRS R&amp;D expenses of \u20ac748.1\u00a0million), and adjusted SG&amp;A3 expenses of \u20ac178.5\u00a0million Raised full-year 2026 revenue guidance midpoint and updated range to \u20ac1.7\u20131.9 billion, &hellip; Continue reading &quot;BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-03T12:01:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"27 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update\",\"datePublished\":\"2026-11-03T12:01:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/\"},\"wordCount\":5417,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/\",\"name\":\"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==\",\"datePublished\":\"2026-11-03T12:01:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update - Market Newsdesk","og_description":"Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead\u2019s TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer Launched variant-adapted COVID-19 vaccine for the 2026\/2027 vaccination season in multiple regions worldwide Third quarter 2026 revenues of \u20ac1,289.2\u00a0million1 , adjusted2 R&amp;D expenses of \u20ac578.5\u00a0million (IFRS R&amp;D expenses of \u20ac748.1\u00a0million), and adjusted SG&amp;A3 expenses of \u20ac178.5\u00a0million Raised full-year 2026 revenue guidance midpoint and updated range to \u20ac1.7\u20131.9 billion, &hellip; Continue reading \"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-03T12:01:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"27 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update","datePublished":"2026-11-03T12:01:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/"},"wordCount":5417,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/","name":"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==","datePublished":"2026-11-03T12:01:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMTQ5OSM0MDI1NTc4NTIjMjAwMDk4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-third-quarter-2026-financial-results-and-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016616"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016616\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}